A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

Inclusion Criteria:

* Histologically or cytologically confirmation of RCC without a clear cell histologic component, e.g., papillary type, chromophobe type, medullary type or unclassified)
* Patients with stage IV or recurrent disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent
* Previous treatment with temsirolimus
* Measurable disease according to RECIST criteria
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Age 18 years or older
* Adequate cardiac function
* Adequate bone marrow, hepatic, and renal function
* Hematology:

Neutrophil same or more than 1.5 x 10\^9/L Platelet same or more than 75 x 10\^9/L Hemoglobin same or more than 9 g/dL -Liver function tests: Total bilirubin same or less than 1.5 x upper limit normal (xULN) aspartate aminotransferase(AST), alanine aminotransferase (ALT) same or less than 2.5 xULN Alkaline phosphatase same or less than 2.5 xULN

-Renal function tests: Creatinine clearance same or more than 30 mL/min

* Life expectancy more than 3 months
* Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment

Exclusion Criteria:

* Clear cell type RCC
* Composed of mostly sarcomatoid carcinoma
* Collecting duct type RCC
* Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri
* Hypertension that cannot be controlled by medications (blood pressure 150/90 mmHg despite optimal medical therapy)
* Pregnancy or breast feeding
* Other severe acute or chronic medical or psychiatric condition
* Prior treatment on sunitinib, sorafenib, pazopanib or bevacizumab
* Uncontrolled central nerve system (CNS) metastasis (brain and/or leptomeningeal metastasis)
* Patients who require concomitant treatment with potent cytochrome P 3A4 ( CYP3A4) inducers and inhibitors